KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Staar Surgical (STAA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Staar Surgical (STAA) over the last 16 years, with Q3 2025 value amounting to $68.6 million.

  • Staar Surgical's Operating Expenses fell 860.59% to $68.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $318.7 million, marking a year-over-year increase of 939.08%. This contributed to the annual value of $306.2 million for FY2024, which is 1383.54% up from last year.
  • As of Q3 2025, Staar Surgical's Operating Expenses stood at $68.6 million, which was down 860.59% from $73.0 million recorded in Q2 2025.
  • In the past 5 years, Staar Surgical's Operating Expenses registered a high of $99.1 million during Q1 2025, and its lowest value of $39.9 million during Q2 2021.
  • Moreover, its 5-year median value for Operating Expenses was $63.1 million (2023), whereas its average is $63.2 million.
  • As far as peak fluctuations go, Staar Surgical's Operating Expenses crashed by 1023.42% in 2021, and later soared by 4430.94% in 2023.
  • Quarter analysis of 5 years shows Staar Surgical's Operating Expenses stood at $46.7 million in 2021, then rose by 25.56% to $58.6 million in 2022, then grew by 4.39% to $61.2 million in 2023, then increased by 27.46% to $78.0 million in 2024, then fell by 12.04% to $68.6 million in 2025.
  • Its Operating Expenses stands at $68.6 million for Q3 2025, versus $73.0 million for Q2 2025 and $99.1 million for Q1 2025.